Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo

Cancer Research

Volumn 61, Issue 24, 2001, Pages 8887-8895

  Moulder, Stacy L ^a   Yakes, F Michael ^a   Bianco, Roberto ^a   Arteaga, Carlos L ^a,a,b   Simpson, Jean F ^a   Muthuswamy, Senthil K ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CHIMERA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CATALYTIC DOMAIN; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035893560     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. The ErbB signaling network: Receptor heterodimerization in development and cancer
2. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
3. Untangling the ErbB signalling network
4. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
5. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers
6. A hierarchical network of interreceptor interaction determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
7. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
8. Coexpression of erbB 2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
9. ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4
10. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
11. Epidermal growth factor-related peptides and their receptors in human malignancies
12. Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu
13. Oncogenic potential of erbB-2 in human mammary epithelial cells
14. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
15. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
16. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
17. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
18. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer
19. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation
20. EGF-stimulated tyrosine phosphorylation of p185neu: A potential model for receptor interactions
21. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function
22. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor transregulation
23. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
24. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor α in the mammary epithelium of transgenic mice
25. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-α bigenic mice
26. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling
27. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation
28. ZD1839 ("Iressa") as an anticancer agent
29. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers
30. ErbB2/neu kinase modulates p27Kipl and cyclin D1 through multiple signaling pathways
31. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu
32. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
33. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
34. Epidermal growth factor receptors in human breast carcinoma cells: A potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 fusion protein
35. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
36. Cellular survival: A play in three Akts
37. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase Cγ or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members
38. Humanization of an anti-p185HER2 antibody for human cancer therapy
39. The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors
40. Extracellular domains drive homo- but not hetero-dimerization of erbB receptors
41. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
42. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
43. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kipl)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency
44. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
45. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors
46. Secondary dimerization between members of the epidermal growth factor receptor family
47. Tyrosine kinase inhibition: An approach to drug development
48. Epidermal-growth-factor-dependent activation of the src-family kinases
49. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225
50. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets